Groups

Home Research group

RESEARCH GROUPS

Catalunya

arrow

GRenSSAP

Obesity and cancer risk and survival: the role of co-morbidities

Funding entity:
Duration: 2026 hasta: 2026

Optimal treatment for patients with solid tumours in Europe through Artificial intelligence

Funding entity: STICHTING EUROPEAN UROLOGICAL FOUNDATION
Duration: 2021 hasta: 2026

ORION (Ozanimod Real-World Safety - A Post-Authorisation Multinational Long-Term Non-Interventional Study) Data: 17/06/2025

Funding entity: Evidera, Inc.
Duration: 2026 hasta: 2026

Paper del colesterol remanent (CR) com a factor de risc cardiovascular

Funding entity:
Duration: 2022 hasta: 2025

PATIADIABETES

Funding entity:
Duration:

Percepcions sobre la contaminació de l'aire i la temperatura i el seu impacte en la salut i el benestar emocional en residents de 3 zones de l'àrea metropolitana de Barcelona amb perspectiva de justícia social i mediambiental

Funding entity: Ajuntament de Barcelona
Duration: 2022 hasta: 2026

Perfil neurocognitiu de la síndrome post covid en persones adultes de Catalunya: estudi amb mètodes mixtes en un cas-control niat (nested) en cohorts. Breu: Aliança ProHEpiC-19 Cognitiu

Funding entity: Departament de Salut
Duration: 2022 hasta: 2026

Phenotyping and Treatment Patterns in Cluster Headache in Europe: A Multinational, Multidatabase Network Study

Funding entity: Stichting European Health and Data Evidence Network (EHDEN Foundation)
Duration: 2025 hasta: 2026

Plataforma IMPACT - Programa 1 Medicina Predictiva

Funding entity:
Duration:

Plataforma ISCIII de soporte para la investigación clínica independiente

Funding entity:
Duration: 2020 hasta: 2025

POCUS-ia "Pre-clinical development of smart ultrasound device for prevent respiratory infections morbidity"

Funding entity:
Duration:

Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries

Funding entity: Research Triangle Institute - USA
Duration: 2022 hasta: 2026

Preliminary signal assessment in VigiBase enhanced by longitudinal observational health data: the EHDEN pharmacovigilance use case

Funding entity: IDIAP Jordi Gol
Duration: 2022 hasta: 2026

Prevalence of rare blood cancers in Europe

Funding entity: ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (EMC)
Duration: 2022 hasta: 2026

Professionals, health care workers healthy and infected with SARS-CoV2 long-term incidence, reinfection, serological protection and impact of vaccination: The ProHEpiC-19+ Cohort study

Funding entity: Institut Català de la Salut (ICS)
Duration: 2021 hasta: 2026

Programa de prevenció de malalties cardiovasculars basat en el cribratge d'arteriopatia perifèrica asimptomàtica. [Health program for prEvention of cardiovascuLar disEases based on a risk screeNing strategy with Ankle-brachial index]. HELENA Study

Funding entity: Departament de Salut
Duration: 2022 hasta: 2026

Prova Anna

Funding entity:
Duration: 2021 hasta: 2026

Proyecto validación Lantitaps

Funding entity:
Duration:

Quality, efficacy and safety studies on medicines, Lot 5 Pharmacoepidemiological research (V. HEBRON)

Funding entity:
Duration:

Real World Burden of Chronic Kidney Disease A Population-Based Study In Catalonia, Northeast Spain

Funding entity: Boehringer Ingelheim España, S.A.
Duration: 2023 hasta: 2026
© Ricapps 2026 | Desarrollado por VGS